In the therapeutic landscape of pediatric obesity, GLP-1R agonists have emerged as particularly effective agents when compared with other available strategies
Milaneschi Y, Simmons WK, Van REFC, Wjh B
The potential for GLP-1 agonists to treat disorders like type-2 diabetes (T2D) was not lost on the endocrinology community (Reviewed here)
Therapeutic potential of semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: A narrative review
This legal grey area does not confer safety, and the MHRA continues to monitor and act against suppliers making misleading health claims
"Health Canada never endorses a health product and does not allow its logo to be used in the advertising or packaging of health products," the public advisory said